{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:35:21Z","timestamp":1790904921291,"version":"4.1.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019186","name":"HORIZON EUROPE Innovative Europe","doi-asserted-by":"publisher","award":["10083717 & 10080153"],"award-info":[{"award-number":["10083717 & 10080153"]}],"id":[{"id":"10.13039\/100019186","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Gaucher disease (GD) is a lysosomal storage disorder caused by mutations in the\n                      <jats:italic>GBA1<\/jats:italic>\n                      gene, leading to deficient glucocerebrosidase activity and accumulation of glucosylceramide in macrophages. Beyond lysosomal dysfunction, GD is associated with widespread metabolic abnormalities, yet the molecular basis of these changes remains incompletely understood. This study employed constraint-based genome-scale metabolic modelling to investigate systemic metabolic reprogramming in GD macrophages, aiming to uncover disrupted pathways and mechanistic drivers of disease phenotypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 150 pairs of high-quality macrophage-specific models under Gaucher and control conditions were developed using a semi-automated pipeline to integrate transcriptomic, exometabolomic and bibliomic data. These Gaucher models captured disease-specific perturbations by incorporating gene expression profiles from GD macrophages. Simulations predicted a shift from oxidative phosphorylation to glycolysis under energy stress in GD, attributed to impaired mitochondrial ATP transport and reduced activity of respiratory complexes. Lipid metabolism was profoundly altered, with increased\n                      <jats:italic>de novo<\/jats:italic>\n                      ceramide synthesis, defective ganglioside processing, and dysregulated cholesterol metabolism. Despite clinically observed hypocholesterolaemia, the models predicted upregulated intracellular cholesterol biosynthesis, suggesting a disconnect between intracellular and systemic cholesterol pools. Reporter metabolite analysis further highlighted cholesterol, sphingolipids, and acylcarnitine as hubs of transcriptional dysregulation. Robust metabolic transformation analysis predicted\n                      <jats:italic>ASAH1<\/jats:italic>\n                      (acid ceramidase) and\n                      <jats:italic>CPT1A<\/jats:italic>\n                      (carnitine palmitoyl transferase 1\u00a0A) as potential modifier genes influencing lipid catabolism and mitochondrial function. Several model predictions were corroborated by independent experimental findings, supporting their biological plausibility.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates the utility of constraint-based metabolic modelling in elucidating the systems-level metabolic dysfunction underlying GD. The results highlight a core axis of mitochondrial and lipid metabolic disruption, particularly involving cholesterol homeostasis, as a central feature of disease pathophysiology. These predictions provide mechanistic insight into the cellular consequences of lysosomal dysfunction and identify candidate metabolic biomarkers and therapeutic targets. The modelling framework developed here supports hypothesis generation and future applications in precision medicine for lysosomal storage disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04206-8","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:55:07Z","timestamp":1768910107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Constraint-based modelling of metabolic dysregulation in Gaucher disease: mitochondrial dysfunction and disrupted cholesterol homeostasis"],"prefix":"10.1186","volume":"21","author":[{"given":"Yanjun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M. F. G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"van der Lienden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-9812","authenticated-orcid":false,"given":"Ronan M. T.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"4206_CR1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.cbpa.2019.10.006","volume":"53","author":"JMFG Aerts","year":"2019","unstructured":"Aerts JMFG, Kuo C-L, Lelieveld LT, Boer DEC, van der Lienden MJC, Overkleeft HS, et al. Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease. Curr Opin Chem Biol. 2019;53:204\u201315. https:\/\/doi.org\/10.1016\/j.cbpa.2019.10.006.","journal-title":"Curr Opin Chem Biol"},{"key":"4206_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10545-011-9308-6","volume":"34","author":"JMFG Aerts","year":"2011","unstructured":"Aerts JMFG, Kallemeijn WW, Wegdam W, Joao Ferraz M, van Breemen MJ, Dekker N, et al. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis. 2011;34:605\u201319. https:\/\/doi.org\/10.1007\/s10545-011-9308-6.","journal-title":"J Inherit Metab Dis"},{"key":"4206_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4274\/tjh.2015.0043","volume":"32","author":"S Gozdasoglu","year":"2015","unstructured":"Gozdasoglu S. Gaucher disease and gaucher cells. Turk J Haematol. 2015;32:187\u20138. https:\/\/doi.org\/10.4274\/tjh.2015.0043.","journal-title":"Turk J Haematol"},{"key":"4206_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of gaucher disease Pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441. https:\/\/doi.org\/10.3390\/ijms18020441.","journal-title":"Int J Mol Sci"},{"key":"4206_CR5","doi-asserted-by":"publisher","first-page":"F163","DOI":"10.1136\/fn.82.2.F163","volume":"82","author":"D Stone","year":"2000","unstructured":"Stone D, Carey W, Christodoulou J, Sillence D, Nelson P, Callahan M, et al. Type 2 gaucher disease: the collodion baby phenotype revisited. Arch Dis Child Fetal Neonatal Ed. 2000;82:F163\u20136. https:\/\/doi.org\/10.1136\/fn.82.2.F163.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"4206_CR6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1399-0004.2007.00899.x","volume":"72","author":"A Tylki-Szyma\u0144ska","year":"2007","unstructured":"Tylki-Szyma\u0144ska A, Czartoryska B, Vanier M-T, Poorthuis B, Groener J, \u0141ugowska A, et al. Non-neuronopathic gaucher disease due to Saposin C deficiency. Clin Genet. 2007;72:538\u201342. https:\/\/doi.org\/10.1111\/j.1399-0004.2007.00899.x.","journal-title":"Clin Genet"},{"key":"4206_CR7","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.3390\/ijms25126615","volume":"25","author":"E Pavan","year":"2024","unstructured":"Pavan E, Peruzzo P, Cattarossi S, Bergamin N, Bordugo A, Sechi A, et al. Deficiency of glucocerebrosidase activity beyond gaucher disease: PSAP and LIMP-2 dysfunctions. Int J Mol Sci Multidisciplinary Digit Publishing Inst. 2024;25:6615. https:\/\/doi.org\/10.3390\/ijms25126615.","journal-title":"Int J Mol Sci Multidisciplinary Digit Publishing Inst"},{"key":"4206_CR8","doi-asserted-by":"publisher","first-page":"e116023","DOI":"10.1371\/journal.pone.0116023","volume":"9","author":"S Barnes","year":"2014","unstructured":"Barnes S, Xu Y-H, Zhang W, Liou B, Setchell KDR, Bao L, et al. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a gaucher disease mouse model. PLoS ONE. 2014;9:e116023. https:\/\/doi.org\/10.1371\/journal.pone.0116023.","journal-title":"PLoS ONE"},{"key":"4206_CR9","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/humu.23611","volume":"39","author":"BA Davidson","year":"2018","unstructured":"Davidson BA, Hassan S, Garcia EJ, Tayebi N, Sidransky E. Exploring genetic modifiers of gaucher disease: the next horizon. Hum Mutat. 2018;39:1739\u201351. https:\/\/doi.org\/10.1002\/humu.23611.","journal-title":"Hum Mutat"},{"key":"4206_CR10","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.celrep.2016.07.085","volume":"16","author":"AD Klein","year":"2016","unstructured":"Klein AD, Ferreira N-S, Ben-Dor S, Duan J, Hardy J, Cox TM, et al. Identification of modifier genes in a mouse model of gaucher disease. Cell Rep. 2016;16:2546\u201353. https:\/\/doi.org\/10.1016\/j.celrep.2016.07.085.","journal-title":"Cell Rep"},{"key":"4206_CR11","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/hmg\/ddae113","volume":"33","author":"Y Lin","year":"2024","unstructured":"Lin Y, Zhao X, Liou B, Fannin V, Zhang W, Setchell KDR, et al. Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating gaucher disease. Hum Mol Genet. 2024;33:1771\u201388. https:\/\/doi.org\/10.1093\/hmg\/ddae113.","journal-title":"Hum Mol Genet"},{"key":"4206_CR12","doi-asserted-by":"publisher","unstructured":"Zhao X, Lin Y, Liou B, Fu W, Jian J, Fannin V, et al. PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2023;120:e2210442120. https:\/\/doi.org\/10.1073\/pnas.2210442120","DOI":"10.1073\/pnas.2210442120"},{"key":"4206_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ebiom.2016.08.004","volume":"11","author":"J Jian","year":"2016","unstructured":"Jian J, Zhao S, Tian Q-Y, Liu H, Zhao Y, Chen W-C, et al. Association between Progranulin Gaucher Disease EBioMedicine. 2016;11:127\u201337. https:\/\/doi.org\/10.1016\/j.ebiom.2016.08.004.","journal-title":"Association between Progranulin Gaucher Disease EBioMedicine"},{"key":"4206_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/8904_2013_281","volume":"14","author":"D Doneda","year":"2013","unstructured":"Doneda D, Vairo FP, Lopes AL, Reischak-Oliveira \u00c1, Schestatsky P, Bianchin MM, et al. Assessment of basal metabolic rate and nutritional status in patients with gaucher disease type III. JIMD Rep. 2013;14:37\u201342. https:\/\/doi.org\/10.1007\/8904_2013_281.","journal-title":"JIMD Rep"},{"key":"4206_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00109-024-02512-x","volume":"103","author":"F Ducatez","year":"2025","unstructured":"Ducatez F, Berger MG, Pilon C, Plichet T, Lesueur C, Berger J, et al. Deciphering metabolic shifts in gaucher disease type 1: a multi-omics study. J Mol Med. 2025;103:187\u2013203. https:\/\/doi.org\/10.1007\/s00109-024-02512-x.","journal-title":"J Mol Med"},{"key":"4206_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13023-019-1211-5","volume":"14","author":"M Ka\u0142u\u017cna","year":"2019","unstructured":"Ka\u0142u\u017cna M, Trzeciak I, Ziemnicka K, Machaczka M, Rucha\u0142a M. Endocrine and metabolic disorders in patients with gaucher disease type 1: a review. Orphanet J Rare Dis. 2019;14:275. https:\/\/doi.org\/10.1186\/s13023-019-1211-5.","journal-title":"Orphanet J Rare Dis"},{"key":"4206_CR17","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/0026-0495(89)90165-0","volume":"38","author":"DJ Barton","year":"1989","unstructured":"Barton DJ, Ludman MD, Benkov K, Grabowski GA, LeLeiko NS. Resting energy expenditure in gaucher\u2019s disease type 1: effect of gaucher\u2019s cell burden on energy requirements. Metabolism. 1989;38:1238\u201343. https:\/\/doi.org\/10.1016\/0026-0495(89)90165-0.","journal-title":"Metabolism"},{"key":"4206_CR18","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1210\/jcem.80.9.7673407","volume":"80","author":"EP Corssmit","year":"1995","unstructured":"Corssmit EP, Hollak CE, Endert E, van Oers MH, Sauerwein HP, Romijn JA. Increased basal glucose production in type 1 gaucher\u2019s disease. J Clin Endocrinol Metab. 1995;80:2653\u20137. https:\/\/doi.org\/10.1210\/jcem.80.9.7673407.","journal-title":"J Clin Endocrinol Metab"},{"key":"4206_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10545-007-0621-z","volume":"30","author":"P Grigorescu Sido","year":"2007","unstructured":"Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, et al. Outcome of enzyme replacement therapy in patients with gaucher disease type I. The Romanian experience. J Inherit Metab Dis. 2007;30:783\u20139. https:\/\/doi.org\/10.1007\/s10545-007-0621-z.","journal-title":"J Inherit Metab Dis"},{"key":"4206_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bcmd.2007.09.002","volume":"40","author":"M Langeveld","year":"2008","unstructured":"Langeveld M, de Fost M, Aerts JMFG, Sauerwein HP, Hollak CEM. Overweight, insulin resistance and type II diabetes in type I gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis. 2008;40:428\u201332. https:\/\/doi.org\/10.1016\/j.bcmd.2007.09.002.","journal-title":"Blood Cells Mol Dis"},{"key":"4206_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bcmd.2016.10.012","volume":"68","author":"F Nascimbeni","year":"2018","unstructured":"Nascimbeni F, Dalla Salda A, Carubbi F. Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 gaucher disease. Blood Cells Mol Dis. 2018;68:74\u201380. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.012.","journal-title":"Blood Cells Mol Dis"},{"key":"4206_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/j.1471-4159.1978.tb12395.x","volume":"30","author":"MC Stephens","year":"1978","unstructured":"Stephens MC, Bernatsky A, Burachinsky V, Legler G, Kanfer JN. The gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects. J Neurochem. 1978;30:1023\u20137. https:\/\/doi.org\/10.1111\/j.1471-4159.1978.tb12395.x.","journal-title":"J Neurochem"},{"key":"4206_CR23","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1515\/bchm2.1967.348.1.1359","volume":"348","author":"G Legler","year":"1967","unstructured":"Legler G. [Studies on the mechanism of action of glycoside-splitting enzymes, II. Isolation and enzymatic properties of 2 beta-glucosidases from Aspergillus wentii]. Hoppe Seylers Z Physiol Chem. 1967;348:1359\u201366.","journal-title":"Hoppe Seylers Z Physiol Chem"},{"key":"4206_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/357407a0","volume":"357","author":"VLJ Tybulewicz","year":"1992","unstructured":"Tybulewicz VLJ, Tremblay ML, LaMarca, Willemsen R, Stubblefield BK, Winfield S, et al. Animal model of gaucher\u2019s disease from targeted disruption of the mouse glucocerebrosidase gene. Nature. 1992;357:407\u201310. https:\/\/doi.org\/10.1038\/357407a0.","journal-title":"Nature"},{"key":"4206_CR25","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/2211-5463.12078","volume":"6","author":"G Kramer","year":"2016","unstructured":"Kramer G, Wegdam W, Donker-Koopman W, Ottenhoff R, Gaspar P, Verhoek M, et al. Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 gaucher disease patients and mouse models. FEBS Open Bio. 2016;6:902\u201313. https:\/\/doi.org\/10.1002\/2211-5463.12078.","journal-title":"FEBS Open Bio"},{"key":"4206_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nm.3449","volume":"20","author":"EB Vitner","year":"2014","unstructured":"Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD, et al. RIPK3 as a potential therapeutic target for gaucher\u2019s disease. Nat Med. 2014;20:204\u20138. https:\/\/doi.org\/10.1038\/nm.3449.","journal-title":"Nat Med"},{"key":"4206_CR27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/path.4751","volume":"239","author":"A Vardi","year":"2016","unstructured":"Vardi A, Zigdon H, Meshcheriakova A, Klein AD, Yaacobi C, Eilam R, et al. Delineating pathological pathways in a chemically induced mouse model of gaucher disease. J Pathol. 2016;239:496\u2013509. https:\/\/doi.org\/10.1002\/path.4751.","journal-title":"J Pathol"},{"key":"4206_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1651-2227.2007.00641.x","volume":"97","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, van Breemen MJ, Bussink AP, Ghauharali K, Sprenger R, Boot RG, et al. Biomarkers for lysosomal storage disorders: identification and application as exemplified by Chitotriosidase in gaucher disease. Acta Paediatr. 2008;97:7\u201314. https:\/\/doi.org\/10.1111\/j.1651-2227.2007.00641.x.","journal-title":"Acta Paediatr"},{"key":"4206_CR29","doi-asserted-by":"publisher","first-page":"17483","DOI":"10.1073\/pnas.0708086104","volume":"104","author":"IB Enquist","year":"2007","unstructured":"Enquist IB, Lo Bianco C, Ooka A, Nilsson E, M\u00e5nsson J-E, Ehinger M, et al. Murine models of acute neuronopathic gaucher disease. Proc Natl Acad Sci U S A. 2007;104:17483\u20138. https:\/\/doi.org\/10.1073\/pnas.0708086104.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4206_CR30","doi-asserted-by":"publisher","unstructured":"Enquist IB, Nilsson E, Ooka A, M\u00e5nsson J-E, Olsson K, Ehinger M, et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proceedings of the National Academy of Sciences. 2006;103:13819\u201324. https:\/\/doi.org\/10.1073\/pnas.0606016103","DOI":"10.1073\/pnas.0606016103"},{"key":"4206_CR31","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1242\/dmm.008185","volume":"4","author":"T Farfel-Becker","year":"2011","unstructured":"Farfel-Becker T, Vitner EB, Futerman AH. Animal models for gaucher disease research. Dis Model Mech. 2011;4:746\u201352. https:\/\/doi.org\/10.1242\/dmm.008185.","journal-title":"Dis Model Mech"},{"key":"4206_CR32","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1021\/jacs.9b00056","volume":"141","author":"M Artola","year":"2019","unstructured":"Artola M, Kuo C-L, Lelieveld LT, Rowland RJ, van der Marel GA, Cod\u00e9e JDC, et al. Functionalized cyclophellitols are selective glucocerebrosidase inhibitors and induce a Bona Fide neuropathic gaucher model in zebrafish. J Am Chem Soc. 2019;141:4214\u20138. https:\/\/doi.org\/10.1021\/jacs.9b00056.","journal-title":"J Am Chem Soc"},{"key":"4206_CR33","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/febs.14744","volume":"286","author":"C-L Kuo","year":"2019","unstructured":"Kuo C-L, Kallemeijn WW, Lelieveld LT, Mirzaian M, Zoutendijk I, Vardi A, et al. In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling. FEBS J. 2019;286:584\u2013600. https:\/\/doi.org\/10.1111\/febs.14744.","journal-title":"FEBS J"},{"key":"4206_CR34","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nchembio.466","volume":"6","author":"MD Witte","year":"2010","unstructured":"Witte MD, Kallemeijn WW, Aten J, Li K-Y, Strijland A, Donker-Koopman WE, et al. Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol. 2010;6:907\u201313. https:\/\/doi.org\/10.1038\/nchembio.466.","journal-title":"Nat Chem Biol"},{"key":"4206_CR35","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1101\/gr.169101","volume":"11","author":"LT Reiter","year":"2001","unstructured":"Reiter LT, Potocki L, Chien S, Gribskov M, Bier E. A systematic analysis of human Disease-Associated gene sequences in Drosophila melanogaster. Genome Res. 2001;11:1114\u201325. https:\/\/doi.org\/10.1101\/gr.169101.","journal-title":"Genome Res"},{"key":"4206_CR36","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3390\/cells13191619","volume":"13","author":"A Kuppuramalingam","year":"2024","unstructured":"Kuppuramalingam A, Cabasso O, Horowitz M. Functional analysis of human GBA1 missense mutations in drosophila: insights into gaucher disease pathogenesis and phenotypic consequences. Cells. 2024;13:1619. https:\/\/doi.org\/10.3390\/cells13191619.","journal-title":"Cells"},{"key":"4206_CR37","doi-asserted-by":"publisher","first-page":"11654","DOI":"10.1523\/JNEUROSCI.4527-15.2016","volume":"36","author":"KJ Kinghorn","year":"2016","unstructured":"Kinghorn KJ, Gr\u00f6nke S, Castillo-Quan JI, Woodling NS, Li L, Sirka E, et al. A drosophila model of neuronopathic gaucher disease demonstrates Lysosomal-Autophagic defects and altered mTOR signalling and is functionally rescued by Rapamycin. J Neurosci. 2016;36:11654\u201370.","journal-title":"J Neurosci"},{"key":"4206_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nature05954","volume":"448","author":"G Dietzl","year":"2007","unstructured":"Dietzl G, Chen D, Schnorrer F, Su K-C, Barinova Y, Fellner M, et al. A genome-wide Transgenic RNAi library for conditional gene inactivation in drosophila. Nature. 2007;448:151\u20136. https:\/\/doi.org\/10.1038\/nature05954.","journal-title":"Nature"},{"key":"4206_CR39","doi-asserted-by":"publisher","first-page":"e1005944","DOI":"10.1371\/journal.pgen.1005944","volume":"12","author":"MY Davis","year":"2016","unstructured":"Davis MY, Trinh K, Thomas RE, Yu S, Germanos AA, Whitley BN, et al. Glucocerebrosidase deficiency in drosophila results in a synuclein independent protein aggregation and neurodegeneration. PLoS Genet. 2016;12:e1005944. https:\/\/doi.org\/10.1371\/journal.pgen.1005944.","journal-title":"PLoS Genet"},{"key":"4206_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.celrep.2013.06.020","volume":"4","author":"AR Bassett","year":"2013","unstructured":"Bassett AR, Tibbit C, Ponting CP, Liu J-L. Highly efficient targeted mutagenesis of drosophila with the CRISPR\/Cas9 system. Cell Rep. 2013;4:220\u20138. https:\/\/doi.org\/10.1016\/j.celrep.2013.06.020.","journal-title":"Cell Rep"},{"key":"4206_CR41","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nbt.4072","volume":"36","author":"E Brunk","year":"2018","unstructured":"Brunk E, Sahoo S, Zielinski DC, Altunkaya A, Dr\u00e4ger A, Mih N, et al. Recon3D enables a three-dimensional view of gene variation in human metabolism. Nat Biotechnol. 2018;36:272\u201381. https:\/\/doi.org\/10.1038\/nbt.4072.","journal-title":"Nat Biotechnol"},{"key":"4206_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nbt.1614","volume":"28","author":"JD Orth","year":"2010","unstructured":"Orth JD, Thiele I, Palsson B\u00d8. What is flux balance analysis? Nat Biotechnol. 2010;28:245\u20138. https:\/\/doi.org\/10.1038\/nbt.1614.","journal-title":"Nat Biotechnol"},{"key":"4206_CR43","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41596-018-0098-2","volume":"14","author":"L Heirendt","year":"2019","unstructured":"Heirendt L, Arreckx S, Pfau T, Mendoza SN, Richelle A, Heinken A, et al. Creation and analysis of biochemical constraint-based models using the COBRA toolbox v.3.0. Nat Protoc. 2019;14:639\u2013702. https:\/\/doi.org\/10.1038\/s41596-018-0098-2.","journal-title":"Nat Protoc"},{"key":"4206_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrg3643","volume":"15","author":"A Bordbar","year":"2014","unstructured":"Bordbar A, Monk JM, King ZA, Palsson BO. Constraint-based models predict metabolic and associated cellular functions. Nat Rev Genet. 2014;15:107\u201320. https:\/\/doi.org\/10.1038\/nrg3643.","journal-title":"Nat Rev Genet"},{"key":"4206_CR45","doi-asserted-by":"publisher","first-page":"11556","DOI":"10.3390\/ijms222111556","volume":"22","author":"A Bayraktar","year":"2021","unstructured":"Bayraktar A, Lam S, Altay O, Li X, Yuan M, Zhang C, et al. Revealing the molecular mechanisms of alzheimer disease based on network analysis. Int J Mol Sci. 2021;22:11556. https:\/\/doi.org\/10.3390\/ijms222111556.","journal-title":"Int J Mol Sci"},{"key":"4206_CR46","doi-asserted-by":"publisher","unstructured":"Preciat G, Wegrzyn AB, Luo X, et al. XomicsToModel: omics data integration and generation of thermodynamically consistent metabolic models. Nat Protoc. 2025. https:\/\/doi.org\/10.1038\/s41596-025-01288-9.","DOI":"10.1038\/s41596-025-01288-9"},{"key":"4206_CR47","doi-asserted-by":"publisher","first-page":"100115","DOI":"10.1016\/j.mbplus.2022.100115","volume":"15","author":"HH Henriksen","year":"2022","unstructured":"Henriksen HH, Mar\u00edn de Mas I, Herand H, Krocker J, Wade CE, Johansson PI. Metabolic systems analysis identifies a novel mechanism contributing to shock in patients with endotheliopathy of trauma (EoT) involving thromboxane A2 and LTC4. Matrix Biology Plus. 2022;15:100115. https:\/\/doi.org\/10.1016\/j.mbplus.2022.100115.","journal-title":"Matrix Biology Plus"},{"key":"4206_CR48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41598-022-26816-5","volume":"13","author":"P Fernandes","year":"2023","unstructured":"Fernandes P, Sharma Y, Zulqarnain F, McGrew B, Shrivastava A, Ehsan L, et al. Identifying metabolic shifts in crohn\u2019s disease using \u2019omics-driven contextualized computational metabolic network models. Sci Rep. 2023;13:203. https:\/\/doi.org\/10.1038\/s41598-022-26816-5.","journal-title":"Sci Rep"},{"key":"4206_CR49","doi-asserted-by":"publisher","unstructured":"Medeiros Filho F, Nascimento APB, do, Costa M, de OC TC, de Menezes MA, Nicol\u00e1s MF, et al. A Systematic Strategy to Find Potential Therapeutic Targets for Pseudomonas aeruginosa Using Integrated Computational Models. Front Mol Biosci. 2021;8. https:\/\/doi.org\/10.3389\/fmolb.2021.728129","DOI":"10.3389\/fmolb.2021.728129"},{"key":"4206_CR50","doi-asserted-by":"publisher","first-page":"10250","DOI":"10.15252\/msb.202110260","volume":"17","author":"K Cheng","year":"2021","unstructured":"Cheng K, Martin-Sancho L, Pal LR, Pu Y, Riva L, Yin X, et al. Genome scale metabolic modeling reveals SARS CoV 2 induced metabolic changes and antiviral targets. Mol Syst Biol. 2021;17:10250\u201360. https:\/\/doi.org\/10.15252\/msb.202110260.","journal-title":"Mol Syst Biol"},{"key":"4206_CR51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13075-022-02938-z","volume":"24","author":"X Wu","year":"2022","unstructured":"Wu X, Wang Z, Shi J, Yu X, Li C, Liu J, et al. Macrophage polarization toward M1 phenotype through NF-kB signaling in patients with Beh\u00e7et\u2019s disease. Arthritis Res Ther. 2022;24:249. https:\/\/doi.org\/10.1186\/s13075-022-02938-z.","journal-title":"Arthritis Res Ther"},{"key":"4206_CR52","doi-asserted-by":"publisher","first-page":"eaay5947","DOI":"10.1126\/science.aay5947","volume":"367","author":"E Sjostedt","year":"2020","unstructured":"Sjostedt E, Zhong W, Fagerberg L, Karlsson M, Mitsios N, Adori C, et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science. 2020;367:eaay5947. https:\/\/doi.org\/10.1126\/science.aay5947.","journal-title":"Science"},{"key":"4206_CR53","doi-asserted-by":"publisher","unstructured":"Saier MH, Reddy VS, Moreno-Hagelsieb G, Hendargo KJ, Zhang Y, Iddamsetty V, et al. The transporter classification database (TCDB): 2021 update. Nucleic Acids Res. 2021;D461\u20137. https:\/\/doi.org\/10.1093\/nar\/gkaa1004.","DOI":"10.1093\/nar\/gkaa1004"},{"key":"4206_CR54","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/bioinformatics\/btad450","volume":"39","author":"RMT Fleming","year":"2023","unstructured":"Fleming RMT, Haraldsdottir HS, Minh LH, Vuong PT, Hankemeier T, Thiele I. Cardinality optimization in constraint-based modelling: application to human metabolism. Bioinformatics. 2023;39:450\u201360. https:\/\/doi.org\/10.1093\/bioinformatics\/btad450.","journal-title":"Bioinformatics"},{"key":"4206_CR55","doi-asserted-by":"crossref","unstructured":"Preciat G, Moreno EL. Mechanistic model-driven exometabolomic characterisation of human dopamin- ergic neuronal metabolism. bioRxiv. 2022.","DOI":"10.1101\/2021.06.30.450562"},{"key":"4206_CR56","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s11306-011-0353-9","volume":"8","author":"M Sugimoto","year":"2012","unstructured":"Sugimoto M, Sakagami H, Yokote Y, Onuma H, Kaneko M, Mori M, et al. Non-targeted metabolite profiling in activated macrophage secretion. Metabolomics. 2012;8:624\u201333. https:\/\/doi.org\/10.1007\/s11306-011-0353-9.","journal-title":"Metabolomics"},{"key":"4206_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nprot.2009.203","volume":"5","author":"I Thiele","year":"2010","unstructured":"Thiele I, Palsson B\u00d8. A protocol for generating a high-quality genome-scale metabolic reconstruction. Nat Protoc. 2010;5:93\u2013121. https:\/\/doi.org\/10.1038\/nprot.2009.203.","journal-title":"Nat Protoc"},{"key":"4206_CR58","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jtbi.2011.09.029","volume":"292","author":"RMT Fleming","year":"2012","unstructured":"Fleming RMT, Maes CM, Saunders MA, Ye Y, Palsson B\u00d8. A variational principle for computing nonequilibrium fluxes and potentials in genome-scale biochemical networks. J Theor Biol. 2012;292:71\u20137. https:\/\/doi.org\/10.1016\/j.jtbi.2011.09.029.","journal-title":"J Theor Biol"},{"key":"4206_CR59","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1182\/blood-2009-02-205708","volume":"114","author":"PM Campeau","year":"2009","unstructured":"Campeau PM, Rafei M, Boivin M-N, Sun Y, Grabowski GA, Galipeau J. Characterization of gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood. 2009;114:3181\u201390. https:\/\/doi.org\/10.1182\/blood-2009-02-205708.","journal-title":"Blood"},{"key":"4206_CR60","doi-asserted-by":"publisher","first-page":"9912","DOI":"10.3390\/ijms22189912","volume":"22","author":"JC Serfecz","year":"2021","unstructured":"Serfecz JC, Saadin A, Santiago CP, Zhang Y, Bentzen SM, Vogel SN, et al. C5a activates a Pro-Inflammatory gene expression profile in human gaucher iPSC-Derived macrophages. Int J Mol Sci. 2021;22:9912. https:\/\/doi.org\/10.3390\/ijms22189912.","journal-title":"Int J Mol Sci"},{"key":"4206_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2012.10.010","volume":"62","author":"MWJ Cleeter","year":"2013","unstructured":"Cleeter MWJ, Chau K-Y, Gluck C, Mehta A, Hughes DA, Duchen M, et al. Glucocerebrosidase Inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int. 2013;62:1\u20137. https:\/\/doi.org\/10.1016\/j.neuint.2012.10.010.","journal-title":"Neurochem Int"},{"key":"4206_CR62","doi-asserted-by":"publisher","first-page":"W212","DOI":"10.1093\/nar\/gkz446","volume":"47","author":"AB Keenan","year":"2019","unstructured":"Keenan AB, Torre D, Lachmann A, Leong AK, Wojciechowicz ML, Utti V, et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 2019;47:W212\u201324. https:\/\/doi.org\/10.1093\/nar\/gkz446.","journal-title":"Nucleic Acids Res"},{"key":"4206_CR63","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1073\/pnas.0406811102","volume":"102","author":"KR Patil","year":"2005","unstructured":"Patil KR, Nielsen J. Uncovering transcriptional regulation of metabolism by using metabolic network topology. Proc Natl Acad Sci. 2005;102:2685\u20139. https:\/\/doi.org\/10.1073\/pnas.0406811102.","journal-title":"Proc Natl Acad Sci"},{"key":"4206_CR64","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1093\/bioinformatics\/btz231","volume":"35","author":"LV Valc\u00e1rcel","year":"2019","unstructured":"Valc\u00e1rcel LV, Torrano V, Tobalina L, Carracedo A, Planes FJ. rMTA: robust metabolic transformation analysis. Bioinformatics. 2019;35:4350\u20135. https:\/\/doi.org\/10.1093\/bioinformatics\/btz231.","journal-title":"Bioinformatics"},{"key":"4206_CR65","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/ncomms3632","volume":"4","author":"K Yizhak","year":"2013","unstructured":"Yizhak K, Gabay O, Cohen H, Ruppin E. Model-based identification of drug targets that revert disrupted metabolism and its application to ageing. Nat Commun. 2013;4:2632. https:\/\/doi.org\/10.1038\/ncomms3632.","journal-title":"Nat Commun"},{"key":"4206_CR66","doi-asserted-by":"publisher","first-page":"D614","DOI":"10.1093\/nar\/gky992","volume":"47","author":"A Noronha","year":"2019","unstructured":"Noronha A, Modamio J, Jarosz Y, Guerard E, Sompairac N, Preciat G, et al. The virtual metabolic human database: integrating human and gut Microbiome metabolism with nutrition and disease. Nucleic Acids Res. 2019;47:D614\u201324. https:\/\/doi.org\/10.1093\/nar\/gky992.","journal-title":"Nucleic Acids Res"},{"key":"4206_CR67","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(97)09490-7","volume":"351","author":"M Pocovi","year":"1998","unstructured":"Pocovi M, Cenarro A, Civeira F, Torralba MA, Perez-Calvo JI, Mozas P, et al. Beta-glucocerebrosidase gene locus as a link for gaucher\u2019s disease and Familial hypo-alpha-lipoproteinaemia. Lancet. 1998;351:1919\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(97)09490-7.","journal-title":"Lancet"},{"key":"4206_CR68","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2008.08.027","volume":"204","author":"M de Fost","year":"2009","unstructured":"de Fost M, Langeveld M, Franssen R, Hutten BA, Groener JEM, de Groot E, et al. Low HDL cholesterol levels in type I gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis. 2009;204:267\u201372. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.08.027.","journal-title":"Atherosclerosis"},{"key":"4206_CR69","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10545-010-9271-7","volume":"34","author":"P Stein","year":"2011","unstructured":"Stein P, Yang R, Liu J, Pastores GM, Mistry PK. Evaluation of high density lipoprotein as a Circulating biomarker of gaucher disease activity. J Inherit Metab Dis. 2011;34:429\u201337. https:\/\/doi.org\/10.1007\/s10545-010-9271-7.","journal-title":"J Inherit Metab Dis"},{"key":"4206_CR70","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bcmd.2016.11.005","volume":"68","author":"S Watad","year":"2018","unstructured":"Watad S, Abu-Saleh N, Yousif A, Agbaria A, Rosenbaum H. The role of high density lipoprotein in type 1 gaucher disease. Blood Cells Molecules Dis. 2018;68:43\u20136. https:\/\/doi.org\/10.1016\/j.bcmd.2016.11.005.","journal-title":"Blood Cells Molecules Dis"},{"key":"4206_CR71","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3390\/jcm9041116","volume":"9","author":"M Ivanova","year":"2020","unstructured":"Ivanova M. Altered sphingolipids metabolism damaged mitochondrial functions: lessons learned from gaucher and Fabry diseases. J Clin Med. 2020;9:1116. https:\/\/doi.org\/10.3390\/jcm9041116.","journal-title":"J Clin Med"},{"key":"4206_CR72","doi-asserted-by":"publisher","first-page":"10903","DOI":"10.1038\/srep10903","volume":"5","author":"M de la Mata","year":"2015","unstructured":"de la Mata M, Cot\u00e1n D, Oropesa-\u00c1vila M, Garrido-Maraver J, Cordero MD, Villanueva Paz M, et al. Pharmacological chaperones and coenzyme Q10 treatment improves mutant glucocerebrosidase activity and mitochondrial function in neuronopathic forms of gaucher disease. Sci Rep. 2015;5:10903. https:\/\/doi.org\/10.1038\/srep10903.","journal-title":"Sci Rep"},{"key":"4206_CR73","doi-asserted-by":"publisher","first-page":"7031","DOI":"10.1093\/hmg\/ddv404","volume":"24","author":"N Dasgupta","year":"2015","unstructured":"Dasgupta N, Xu Y, Li R, Peng Y, Pandey MK, Tinch SL, et al. Neuronopathic gaucher disease: dysregulated mRNAs and MiRNAs in brain pathogenesis and effects of Pharmacologic chaperone treatment in a mouse model. Hum Mol Genet. 2015;24:7031\u201348. https:\/\/doi.org\/10.1093\/hmg\/ddv404.","journal-title":"Hum Mol Genet"},{"key":"4206_CR74","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1371\/journal.pone.0210617","volume":"14","author":"MM Ivanova","year":"2019","unstructured":"Ivanova MM, Changsila E, Iaonou C, Goker-Alpan O. Impaired autophagic and mitochondrial functions are partially restored by ERT in gaucher and Fabry diseases. PLoS ONE. 2019;14:2106\u201317. https:\/\/doi.org\/10.1371\/journal.pone.0210617.","journal-title":"PLoS ONE"},{"key":"4206_CR75","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/s0002-9343(97)00134-4","volume":"103","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Corssmit EP, Aerts JM, Endert E, Sauerwein HP, Romijn JA, et al. Differential effects of enzyme supplementation therapy on manifestations of type 1 gaucher disease. Am J Med. 1997;103:185\u201391. https:\/\/doi.org\/10.1016\/s0002-9343(97)00134-4.","journal-title":"Am J Med"},{"key":"4206_CR76","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1046\/j.0902-4441.2003.00193.x","volume":"72","author":"HJ M\u00f8ller","year":"2004","unstructured":"M\u00f8ller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in gaucher\u2019s disease. Eur J Haematol. 2004;72:135\u20139. https:\/\/doi.org\/10.1046\/j.0902-4441.2003.00193.x.","journal-title":"Eur J Haematol"},{"key":"4206_CR77","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.intimp.2014.12.039","volume":"24","author":"AAM Adly","year":"2015","unstructured":"Adly AAM, Ismail EAR, Ibraheem TM. Macrophage-derived soluble CD163 level in young patients with gaucher disease: relation to phenotypes, disease severity and complications. Int Immunopharmacol. 2015;24:416\u201322. https:\/\/doi.org\/10.1016\/j.intimp.2014.12.039.","journal-title":"Int Immunopharmacol"},{"key":"4206_CR78","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2019.236083","volume":"106","author":"T Raskovalova","year":"2021","unstructured":"Raskovalova T, Deegan PB, Mistry PK, Pavlova E, Yang R, Zimran A, et al. Accuracy of Chitotriosidase activity and CCL18 concentration in assessing type I gaucher disease severity. A systematic review with meta-analysis of individual participant data. Haematologica. 2021;106:437\u201345. https:\/\/doi.org\/10.3324\/haematol.2019.236083.","journal-title":"Haematologica"},{"key":"4206_CR79","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/stem.1732","volume":"32","author":"LM Panicker","year":"2014","unstructured":"Panicker LM, Miller D, Awad O, Bose V, Lun Y, Park TS, et al. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells. 2014;32:2338\u201349. https:\/\/doi.org\/10.1002\/stem.1732.","journal-title":"Stem Cells"},{"key":"4206_CR80","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1007\/s12035-024-04008-8","volume":"61","author":"JCC dos Santos","year":"2024","unstructured":"dos Santos JCC, Mano GBC, da Barreto-Vianna C, Garcia AR, de Vasconcelos TFM, S\u00e1 AV. The molecular impact of glucosylceramidase beta 1 (Gba1) in parkinson\u2019s disease: a new genetic state of the Art. Mol Neurobiol. 2024;61:6754\u201370. https:\/\/doi.org\/10.1007\/s12035-024-04008-8.","journal-title":"Mol Neurobiol"},{"key":"4206_CR81","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-024-00437-6","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wu H, Tang B, Guo J. Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated parkinson\u2019s disease. Translational Neurodegeneration. 2024;13:48. https:\/\/doi.org\/10.1186\/s40035-024-00437-6.","journal-title":"Translational Neurodegeneration"},{"key":"4206_CR82","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/cells11081261","volume":"11","author":"L Smith","year":"2022","unstructured":"Smith L, Schapira AHV. GBA variants and Parkinson disease: mechanisms and treatments. Cells. 2022;11:1261. https:\/\/doi.org\/10.3390\/cells11081261.","journal-title":"Cells"},{"key":"4206_CR83","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41467-021-22113-3","volume":"12","author":"S Kim","year":"2021","unstructured":"Kim S, Wong YC, Gao F, Krainc D. Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson disease. Nat Commun. 2021;12:1807. https:\/\/doi.org\/10.1038\/s41467-021-22113-3.","journal-title":"Nat Commun"},{"key":"4206_CR84","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1093\/brain\/awae070","volume":"147","author":"JC Rubilar","year":"2024","unstructured":"Rubilar JC, Outeiro TF, Klein AD. The lysosomal b-glucocerebrosidase strikes mitochondria: implications for parkinson\u2019s therapeutics. Brain. 2024;147:2610\u201320. https:\/\/doi.org\/10.1093\/brain\/awae070.","journal-title":"Brain"},{"key":"4206_CR85","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1038\/s41467-023-37454-4","volume":"14","author":"P Baden","year":"2023","unstructured":"Baden P, Perez MJ, Raji H, Bertoli F, Kalb S, Illescas M, et al. Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism. Nat Commun Nat Publishing Group. 2023;14:1930. https:\/\/doi.org\/10.1038\/s41467-023-37454-4.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"4206_CR86","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.bcmd.2007.10.004","volume":"40","author":"PJ Meikle","year":"2008","unstructured":"Meikle PJ, Whitfield PD, Rozaklis T, Blacklock D, Duplock S, Elstein D, et al. Plasma lipids are altered in gaucher disease: biochemical markers to evaluate therapeutic intervention. Blood Cells Molecules Dis. 2008;40:420\u20137. https:\/\/doi.org\/10.1016\/j.bcmd.2007.10.004.","journal-title":"Blood Cells Molecules Dis"},{"key":"4206_CR87","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ymgme.2007.08.001","volume":"92","author":"LK Hein","year":"2007","unstructured":"Hein LK, Meikle PJ, Hopwood JJ, Fuller M. Secondary sphingolipid accumulation in a macrophage model of gaucher disease. Mol Genet Metab. 2007;92:336\u201345. https:\/\/doi.org\/10.1016\/j.ymgme.2007.08.001.","journal-title":"Mol Genet Metab"},{"key":"4206_CR88","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/jcm9030736","volume":"9","author":"DEC Boer","year":"2020","unstructured":"Boer DEC, van Smeden J, Bouwstra JA, Aerts JMFG. Glucocerebrosidase: functions in and beyond the lysosome. J Clin Med. 2020;9:736\u201342. https:\/\/doi.org\/10.3390\/jcm9030736.","journal-title":"J Clin Med"},{"key":"4206_CR89","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ymgme.2007.11.011","volume":"93","author":"M Fuller","year":"2008","unstructured":"Fuller M, Rozaklis T, Lovejoy M, Zarrinkalam K, Hopwood JJ, Meikle PJ. Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with gaucher disease. Mol Genet Metab. 2008;93:437\u201343. https:\/\/doi.org\/10.1016\/j.ymgme.2007.11.011.","journal-title":"Mol Genet Metab"},{"key":"4206_CR90","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0021-9258(18)89553-9","volume":"260","author":"M Saito","year":"1985","unstructured":"Saito M, Rosenberg A. The fate of glucosylceramide (glucocerebroside) in genetically impaired (lysosomal beta-glucosidase deficient) gaucher disease diploid human fibroblasts. J Biol Chem. 1985;260:2295\u2013300.","journal-title":"J Biol Chem"},{"key":"4206_CR91","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/molecules29020453","volume":"29","author":"C Ceni","year":"2024","unstructured":"Ceni C, Clemente F, Mangiavacchi F, Matassini C, Tonin R, Caciotti A, et al. Identification of GM1-Ganglioside secondary accumulation in fibroblasts from neuropathic gaucher patients and effect of a trivalent Trihydroxypiperidine Iminosugar compound on its storage reduction. Molecules. 2024;29:453. https:\/\/doi.org\/10.3390\/molecules29020453.","journal-title":"Molecules"},{"key":"4206_CR92","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","volume":"39","author":"O Nilsson","year":"1982","unstructured":"Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (Psychosine) in cerebrum and cerebellum in infantile and juvenile gaucher disease. J Neurochem. 1982;39:709\u201318. https:\/\/doi.org\/10.1111\/j.1471-4159.1982.tb07950.x.","journal-title":"J Neurochem"},{"key":"4206_CR93","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cca.2007.12.001","volume":"389","author":"K van der Ghauharali","year":"2008","unstructured":"van der Ghauharali K, Langeveld M, Poppema A, Kuiper S, Hollak CEM, Aerts JM, et al. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I gaucher disease. Clin Chim Acta. 2008;389:109\u201313. https:\/\/doi.org\/10.1016\/j.cca.2007.12.001.","journal-title":"Clin Chim Acta"},{"key":"4206_CR94","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ymgme.2013.03.015","volume":"109","author":"DJ Sillence","year":"2013","unstructured":"Sillence DJ. Glucosylceramide modulates endolysosomal pH in gaucher disease. Mol Genet Metab. 2013;109:194\u2013200. https:\/\/doi.org\/10.1016\/j.ymgme.2013.03.015.","journal-title":"Mol Genet Metab"},{"key":"4206_CR95","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","volume":"82","author":"EM Rocha","year":"2015","unstructured":"Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, et al. Glucocerebrosidase gene therapy prevents a synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015;82:495\u2013503. https:\/\/doi.org\/10.1016\/j.nbd.2015.09.009.","journal-title":"Neurobiol Dis"},{"key":"4206_CR96","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41598-024-83460-x","volume":"15","author":"R Pastore","year":"2025","unstructured":"Pastore R, Yao L, Hatcher N, Helley M, Brownlees J, Desai R. Deficiency in NPC2 results in disruption of mitochondria-late endosome\/lysosomes contact sites and endo-lysosomal lipid dyshomeostasis. Sci Rep. 2025;15:325. https:\/\/doi.org\/10.1038\/s41598-024-83460-x.","journal-title":"Sci Rep"},{"key":"4206_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-022-00397-6","volume":"8","author":"A Navarro-Romero","year":"2022","unstructured":"Navarro-Romero A, Fernandez-Gonzalez I, Riera J, Montpeyo M, Albert-Bayo M, Lopez-Royo T, et al. Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology. Npj Parkinsons Dis. 2022;8:1\u201315.","journal-title":"Npj Parkinsons Dis"},{"key":"4206_CR98","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/15548627.2018.1427396","volume":"14","author":"P Garc\u00eda-Sanz","year":"2018","unstructured":"Garc\u00eda-Sanz P, Orgaz L, Fuentes JM, Vicario C, Moratalla R. Cholesterol and multilamellar bodies: lysosomal dysfunction in GBA-Parkinson disease. Autophagy. 2018;14:717\u20138. https:\/\/doi.org\/10.1080\/15548627.2018.1427396.","journal-title":"Autophagy"},{"key":"4206_CR99","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nature12684","volume":"504","author":"D Neculai","year":"2013","unstructured":"Neculai D, Schwake M, Ravichandran M, Zunke F, Collins RF, Peters J, et al. Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36. Nat Nat Publishing Group. 2013;504:172\u20136. https:\/\/doi.org\/10.1038\/nature12684.","journal-title":"Nat Nat Publishing Group"},{"key":"4206_CR100","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1038\/s41467-019-11425-0","volume":"10","author":"S Heybrock","year":"2019","unstructured":"Heybrock S, Kanerva K, Meng Y, Ing C, Liang A, Xiong Z-J, et al. Lysosomal integral membrane protein-2 (LIMP-2\/SCARB2) is involved in lysosomal cholesterol export. Nat Commun Nat Publishing Group. 2019;10:3521. https:\/\/doi.org\/10.1038\/s41467-019-11425-0.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"4206_CR101","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ymgme.2007.10.132","volume":"93","author":"I Ron","year":"2008","unstructured":"Ron I, Horowitz M. Intracellular cholesterol modifies the ERAD of glucocerebrosidase in gaucher disease patients. Mol Genet Metab. 2008;93:426\u201336. https:\/\/doi.org\/10.1016\/j.ymgme.2007.10.132.","journal-title":"Mol Genet Metab"},{"key":"4206_CR102","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1080\/15548627.2015.1086055","volume":"11","author":"T-T Du","year":"2015","unstructured":"Du T-T, Wang L, Duan C-L, Lu L-L, Zhang J-L, Gao G, et al. GBA deficiency promotes SNCA\/a synuclein accumulation through autophagic Inhibition by inactivated PPP2A. Autophagy. 2015;11:1803\u201320. https:\/\/doi.org\/10.1080\/15548627.2015.1086055.","journal-title":"Autophagy"},{"key":"4206_CR103","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/B978-0-444-63945-5.00017-9","volume":"153","author":"L Volpicelli-Daley","year":"2018","unstructured":"Volpicelli-Daley L, Brundin P. Prion-like propagation of pathology in Parkinson disease. Handb Clin Neurol. 2018;153:321\u201335. https:\/\/doi.org\/10.1016\/B978-0-444-63945-5.00017-9.","journal-title":"Handb Clin Neurol"},{"key":"4206_CR104","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1074\/jbc.RA119.012502","volume":"295","author":"H Akiyama","year":"2020","unstructured":"Akiyama H, Ide M, Nagatsuka Y, Sayano T, Nakanishi E, Uemura N, et al. Glucocerebrosidases catalyze a transgalactosylation reaction that yields a newly-identified brain sterol metabolite, galactosylated cholesterol. J Biol Chem. 2020;295:5257\u201377. https:\/\/doi.org\/10.1074\/jbc.RA119.012502.","journal-title":"J Biol Chem"},{"key":"4206_CR105","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1471-2164-12-96","volume":"12","author":"M Simon\u010di\u010d","year":"2011","unstructured":"Simon\u010di\u010d M, Re\u017een T, Juvan P, Rozman D, Fazarinc G, Fievet C, et al. Obesity resistant mechanisms in the lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle. BMC Genomics. 2011;12:96. https:\/\/doi.org\/10.1186\/1471-2164-12-96.","journal-title":"BMC Genomics"},{"key":"4206_CR106","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12986-020-00456-w","volume":"17","author":"Y He","year":"2020","unstructured":"He Y, Yang T, Du Y, Qin L, Ma F, Wu Z, et al. High fat diet significantly changed the global gene expression profile involved in hepatic drug metabolism and Pharmacokinetic system in mice. Nutr Metabolism. 2020;17:37. https:\/\/doi.org\/10.1186\/s12986-020-00456-w.","journal-title":"Nutr Metabolism"},{"key":"4206_CR107","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.biochi.2004.09.018","volume":"86","author":"D Eberle","year":"2004","unstructured":"Eberle D, Hegarty B, Bossard P, Ferr\u00e9 P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86:839\u201348. https:\/\/doi.org\/10.1016\/j.biochi.2004.09.018.","journal-title":"Biochimie"},{"key":"4206_CR108","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1210\/me.2003-0061","volume":"17","author":"P Tontonoz","year":"2003","unstructured":"Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 2003;17:985\u201393. https:\/\/doi.org\/2019041123033981000.","journal-title":"Mol Endocrinol"},{"key":"4206_CR109","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2353\/ajpath.2007.070052","volume":"171","author":"G Liao","year":"2007","unstructured":"Liao G, Yao Y, Liu J, Yu Z, Cheung S, Xie A, et al. Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1\u2013\/\u2013 mouse brain. Am J Pathol. 2007;171:962\u201375. https:\/\/doi.org\/10.2353\/ajpath.2007.070052.","journal-title":"Am J Pathol"},{"key":"4206_CR110","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/j.1471-4159.2010.06976.x","volume":"116","author":"AI Rosenbaum","year":"2011","unstructured":"Rosenbaum AI, Maxfield FR. Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J Neurochem. 2011;116:789\u201395. https:\/\/doi.org\/10.1111\/j.1471-4159.2010.06976.x.","journal-title":"J Neurochem"},{"key":"4206_CR111","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1194\/jlr.D014993","volume":"52","author":"SF Previs","year":"2011","unstructured":"Previs SF, Mahsut A, Kulick A, Dunn K, Andrews-Kelly G, Johnson C, et al. Quantifying cholesterol synthesis in vivo using 2H2O: enabling back-to-back studies in the same subject. J Lipid Res. 2011;52:1420\u20138. https:\/\/doi.org\/10.1194\/jlr.D014993.","journal-title":"J Lipid Res"},{"key":"4206_CR112","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.dmd.2025.100040","volume":"53","author":"W Jiang","year":"2025","unstructured":"Jiang W, Sang R, Zhang C, Yin R, Ouyang Z, Wei Y. Application of small interfering RNA technology in cytochrome P450 gene modulation. Drug Metab Dispos. 2025;53:100040. https:\/\/doi.org\/10.1016\/j.dmd.2025.100040.","journal-title":"Drug Metab Dispos"},{"key":"4206_CR113","doi-asserted-by":"publisher","unstructured":"Ko DC, Binkley J, Sidow A, Scott MP. The integrity of a cholesterol-binding pocket in Niemann\u2013Pick C2 protein is necessary to control lysosome cholesterol levels. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2003;100:2518\u201325. https:\/\/doi.org\/10.1073\/pnas.0530027100","DOI":"10.1073\/pnas.0530027100"},{"key":"4206_CR114","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker N, van Dussen L, Hollak CEM, Overkleeft H, Scheij S, Ghauharali K, et al. Elevated plasma glucosylsphingosine in gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118:e118\u201327. https:\/\/doi.org\/10.1182\/blood-2011-05-352971.","journal-title":"Blood"},{"key":"4206_CR115","doi-asserted-by":"publisher","first-page":"7869","DOI":"10.3390\/ijms21217869","volume":"21","author":"I Menkovic","year":"2020","unstructured":"Menkovic I, Boutin M, Alayoubi A, Mercier FE, Rivard G-\u00c9, Auray-Blais C. Identification of a reliable biomarker profile for the diagnosis of gaucher disease type 1 patients using a mass Spectrometry-Based metabolomic approach. Int J Mol Sci. 2020;21:7869. https:\/\/doi.org\/10.3390\/ijms21217869.","journal-title":"Int J Mol Sci"},{"key":"4206_CR116","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1021\/acs.jproteome.2c00068","volume":"21","author":"I Menkovic","year":"2022","unstructured":"Menkovic I, Boutin M, Alayoubi A, Curado F, Bauer P, Mercier FE, et al. Metabolomic study using Time-of-Flight mass spectrometry reveals novel urinary biomarkers for gaucher disease type 1. J Proteome Res. 2022;21:1321\u20139. https:\/\/doi.org\/10.1021\/acs.jproteome.2c00068.","journal-title":"J Proteome Res"},{"key":"4206_CR117","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ymgme.2015.12.006","volume":"117","author":"MJ Ferraz","year":"2016","unstructured":"Ferraz MJ, Marques ARA, Gaspar P, Mirzaian M, van Roomen C, Ottenhoff R, et al. Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders. Mol Genet Metab. 2016;117:186\u201393. https:\/\/doi.org\/10.1016\/j.ymgme.2015.12.006.","journal-title":"Mol Genet Metab"},{"key":"4206_CR118","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ajpath.2024.11.003","volume":"195","author":"R Zuo","year":"2025","unstructured":"Zuo R, Wang M, Wang Y-T, ShenTu Y, Moura AK, Zhou Y, et al. Ablation of hepatic Asah1 gene disrupts hepatic lipid homeostasis and promotes fibrotic nonalcoholic steatohepatitis in mice. Am J Pathol. 2025;195:542\u201360. https:\/\/doi.org\/10.1016\/j.ajpath.2024.11.003.","journal-title":"Am J Pathol"},{"key":"4206_CR119","doi-asserted-by":"publisher","unstructured":"Lucki NC, Bandyopadhyay S, Wang E, Merrill AH, Sewer MB. Acid Ceramidase (ASAH1) Is a Global Regulator of Steroidogenic Capacity and Adrenocortical Gene Expression. Mol Endocrinol. 2012;26:228\u201343. https:\/\/doi.org\/10.1210\/me.2011-1150.","DOI":"10.1210\/me.2011-1150"},{"key":"4206_CR120","doi-asserted-by":"publisher","first-page":"1160440","DOI":"10.3389\/fphar.2023.1160440","volume":"14","author":"K Liang","year":"2023","unstructured":"Liang K. Mitochondrial CPT1A: insights into structure, function, and basis for drug development. Front Pharmacol. 2023;14:1160440. https:\/\/doi.org\/10.3389\/fphar.2023.1160440.","journal-title":"Front Pharmacol"},{"key":"4206_CR121","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.5114\/aoms\/141219","volume":"19","author":"T Belali","year":"2021","unstructured":"Belali T, Abomughaid M, Alhujaily M. The transcription factor HNF 4a: a key player in haematological disorders. Arch Med Sci. 2021;19:1646\u201352. https:\/\/doi.org\/10.5114\/aoms\/141219.","journal-title":"Arch Med Sci"},{"key":"4206_CR122","doi-asserted-by":"publisher","first-page":"e8531","DOI":"10.1002\/ccr3.8531","volume":"12","author":"C Yang","year":"2024","unstructured":"Yang C, Tsai H, Chou Y, Yang Y. NR1H4 mutation and rapid progressive intrahepatic cholestasis in infancy: A case report and literature review. Clin Case Rep. 2024;12:e8531. https:\/\/doi.org\/10.1002\/ccr3.8531.","journal-title":"Clin Case Rep"},{"key":"4206_CR123","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/nn.4587","volume":"20","author":"K Huang","year":"2017","unstructured":"Huang K, Marcora E, Pimenova AA, Di Narzo AF, Kapoor M, Jin SC, et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of alzheimer\u2019s disease. Nat Neurosci. 2017;20:1052\u201361. https:\/\/doi.org\/10.1038\/nn.4587.","journal-title":"Nat Neurosci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04206-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04206-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04206-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:50:58Z","timestamp":1781628658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04206-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4206"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04206-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used previously published, de-identified human data. Ethics approval and consent to participate were obtained by the original investigators as described in the respective publications.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}